Supplementary Figure 1. Flow of study population selection. A total of 1,658 treatment-naive patients with CHB who were initiated on antiviral therapy (ETV or TDF) between 2007 and 2016 were considered eligible. Of them, 476 patients received TE assessment at enrollment. Twenty-one patients were excluded owing to LS measurement failure or unreliable LS value. Of 455 patients with reliable LS value, 121 were excluded according to our exclusion criteria. Finally, 334 patients were selected for the statistical analysis. CHB, chronic hepatitis B; ETV, entecavir; TDF, tenofovir; TE, transient elastography; LS, liver stiffness; AVT, antiviral therapy; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus.